FOLH1 and breast carcinoma: This group features widely used radiopharmaceuticals, such as DOTA-peptides and PSMA tracers, along with other tracers, some of which are currently under testing such as [18F]fluoroestradiol for oestrogen receptors in breast cancer, [124I]Iodine for differentiated thyroid cancer, and [18F]metafluorobenzylguanidine for neuroblastoma.